Antibody responses after sequential vaccination with PCV13 and PPSV23 in kidney transplant recipients
Open Access
- 27 May 2023
- journal article
- research article
- Published by Springer Science and Business Media LLC in Infection
- Vol. 51 (6), 1703-1716
- https://doi.org/10.1007/s15010-023-02054-3
Abstract
Purpose Vaccination against Streptococcus pneumoniae is recommended in transplant recipients to reduce the morbidity and mortality from invasive pneumococcal disease. Previous studies indicate that transplant recipients can produce specific antibodies after vaccination with the 13-valent pneumococcal conjugate vaccine Prevenar 13 (PCV13) or the pneumococcal polysaccharide vaccine Pneumovax 23 (PPSV23). National guidelines recommend sequential vaccination with PCV13 followed by PPSV23 in kidney transplant patients. However, there are currently no data on the serological response in kidney transplant recipients, who received a sequential vaccination with PCV13 and PPSV23. Methods In the current study, we sequentially vaccinated 46 kidney transplant recipients with PCV13 and PPSV23 and determined global and serotype-specific anti-pneumococcal antibody responses in the year following vaccination. Results Serotype-specific and global anti-pneumococcal antibody concentrations were significantly higher compared to baseline. We observed that serotype-specific antibody responses varied by serotype (between 2.2- and 2.9-fold increase after 12 months). The strongest responses after 12 months were detected against the serotypes 9N (2.9-fold increase) and 14 (2.8-fold increase). Global antibody responses also varied with respect to immunoglobulin class. IgG2 revealed the highest increase (2.7-fold), IgM the lowest (1.7-fold). Sequential vaccination with both vaccines achieved higher antibody levels in comparison with a historical cohort studied at our institute, that was vaccinated with PCV13 alone. During the 12-months follow-up period, none of the patients developed pneumococcal-associated pneumonia or vaccination-related allograft rejection. Conclusion In conclusion, we strongly recommend sequential vaccination over single immunization in kidney transplant recipients.Keywords
Funding Information
- Rudolf-Ackermann-Stiftung
- Universitätsklinikum Essen
This publication has 40 references indexed in Scilit:
- Reference ranges and cutoff levels of pneumococcal antibody global serum assays (IgG and IgG2) and specific antibodies in healthy children and adultsMedical Microbiology and Immunology, 2013
- Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Critical Care, 2013
- Humoral Immunity after kidney transplantation: Impact of two randomized immunosuppressive protocolsAnnals of Transplantation, 2013
- Quantification of IgM and IgA Anti-Pneumococcal Capsular Polysaccharides by a New ELISA Assay: a Valuable Diagnostic and Prognostic Tool for Common Variable ImmunodeficiencyJournal of Clinical Immunology, 2012
- Randomized, Single Blind, Controlled Trial to Evaluate the Prime-Boost Strategy for Pneumococcal Vaccination in Renal Transplant RecipientsPLOS ONE, 2012
- Long-Term Response to Vaccination Against Pneumococcal Antigens in Kidney Transplant RecipientsTransplantation, 2012
- Immunity to Pneumococcal Antigens in Kidney Transplant RecipientsTransplantation, 2010
- Effects of Influenza Immunization on Humoral and Cellular Alloreactivity in HumansTransplantation, 2010
- Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodiesVaccine, 2007
- Levels of Antibodies Specific to Tetanus Toxoid,Haemophilus influenzaeType b, and Pneumococcal Capsular Polysaccharide in Healthy Children and AdultsClinical and Vaccine Immunology, 2003